SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending as community discussion amplifies around its strategic pivot and hiring for robotics AI, underscoring its pivotal role in training artificial intelligence for the burgeoning humanoid and physical AI sectors, further bolstered by its significant partnership with Palantir and strong anticipation for its upcoming earnings.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending amid its Robinhood listing and strategic moves to integrate Real World Assets with NestCredit and implement PYTH Reserve token purchases. The community is actively debating its potential as a leading oracle solution, often comparing it to Chainlink, while also discussing concerns about token distribution and upcoming unlocks.

Royal Gold, Inc. engages in the business of acquiring and managing precious metal streams, royalties, and similar interests. It operates under the Acquisition and Management of Stream Interests, and Acquisition and Management of Royalty Interests segments. The Acquisition and Management of Stream Interests segment focuses on metal streams, which are purchase agreements that provide, in exchange for an upfront deposit payment, the right to purchase all or a portion of one or more metals produced, at a price determined for the life of the transaction. The Acquisition and Management of Royalty Interests segment is involved in non-operating interests in mining projects that provide the right to revenue or metals produced from the project. The company was founded by Stanley Dempsey in 1981 and is headquartered in Denver, CO.

Royal Gold, Inc.

Royal Gold is trending as gold and silver prices reach new highs, with the community calling it a "money printer" due to its robust streaming model. The recent strategic acquisition of Sandstorm Gold, set to significantly boost GEO production and diversify its portfolio, fuels bullish sentiment despite varied analyst price target adjustments.

Tidal Trust II - YieldMax Ultra Short Option Income Strategy ETF

SLTY is drawing attention from high-yield investors as a component of mechanical, 'inverted pair' strategies within the YieldMax ETF suite, valued for its consistent weekly dividends generated from option premiums. The community is actively discussing its utility as a potential bear market hedge and its performance in disciplined, rules-based systems focused on compounding and reinvestment.

Tidal Trust II - YieldMax Short NVDA Option Income Strategy ETF

YieldMax Short NVDA Option Income Strategy ETF

YieldMax Short NVDA Option Income Strategy ETF (DIPS) is trending as investors evaluate its recent dividend payouts and performance in response to NVIDIA's price action and market volatility. The community is actively discussing DIPS for its role in 'inverted pair' hedging strategies and as a high-yield option to gain exposure to potential NVDA downturns or balance existing bullish positions, amidst ongoing conversations about managing its inherent NAV decay.

Tidal Trust II - YieldMax COIN Option Income Strategy ETF

YieldMax COIN Option Income Strategy ETF

YieldMax COIN Option Income Strategy ETF (CONY) is trending as it transitions to weekly dividend distributions, a move that is intensifying community debate around persistent NAV erosion and recent reverse splits, even as some investors advocate for disciplined, long-term income compounding strategies amidst underlying Coinbase volatility.

Tidal Trust II - YieldMax Short COIN Option Income Strategy ETF

YieldMax Short COIN Option Income Strategy ETF

FIAT is trending as investors keenly observe its performance as a YieldMax ETF designed to short Coinbase, often utilized in inverted pair strategies for income generation. The community is actively discussing its latest dividend payouts and debating its effectiveness as a hedge against crypto market volatility, with some anticipating buying opportunities on price dips.

Tidal Trust II - YieldMax NVDA Option Income Strategy ETF

YieldMax NVDA Option Income Strategy ETF

NVDY is trending as investors evaluate its high, fluctuating dividend payouts amidst persistent share price erosion, even with NVIDIA's underlying strength. Community discussion centers on whether reinvesting the recently shifted smaller weekly dividends can effectively counter capital loss and ensure long-term viability.

Tidal Trust II - YieldMax MSTR Short Option Income Strategy ETF

YieldMax MSTR Short Option Income Strategy ETF

WNTR is trending as a favored inverse YieldMax ETF, offering robust dividends while hedging against downward moves or volatility in MicroStrategy (MSTR) and Bitcoin. The community is actively discussing its 'sweet' weekly payouts, especially as a strategic component in 'inverted pairs' with MSTY, allowing for income generation and portfolio balancing through disciplined, options-driven compounding during varied market conditions.

Nova Minerals Ltd. engages in the exploration and development of mineral properties. Its projects include Estelle Gold, RPM, Korbel, Train, Stoney and Studies projects. The company was founded in January 1987 and is headquartered in Melbourne, Australia.

Nova Minerals Limited - ADR

Nova Minerals is trending as it moves to redomicile in the United States, a strategic shift anticipated to attract institutional investors and US ETFs to its Estelle Gold and Critical Minerals Project. Community enthusiasm is also driven by its key antimony resources, backed by a significant government grant for US defense needs, and an upcoming forward stock split, all fueling discussions of its long-term potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CorMedix's (CRMD) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and set a $14.00 price target on shares of CorMedix in a research note on Wednesday...

CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside

CRMD heads into Q4 earnings with DefenCath driving revenues, boosted by strong outpatient dialysis use and added contributions from acquired Melinta products.

Analyst Expectations For Cormedix's Future

CorMedix Investor Day: Melinta Deal Fuels Shift to Multi-Product Pharma, Rezzayo Q2 Data Ahead

CorMedix (NASDAQ:CRMD) used its 2026 Analyst and Investor Day to outline its shift from a single-product renal-focused company to what management described as a diversified, cash-flow-generating...

130,244 Shares in CorMedix Inc $CRMD Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd purchased a new stake in CorMedix Inc (NASDAQ:CRMD - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission...

CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?

CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.

CorMedix (NASDAQ:CRMD) Trading Up 6% - Here's What Happened

CorMedix (NASDAQ:CRMD) Trading 6% Higher - Still a Buy...

CorMedix Inc (NASDAQ:CRMD) Given Consensus Rating of "Buy" by Brokerages

CorMedix Inc (NASDAQ:CRMD - Get Free Report) has earned an average rating of "Buy" from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two investment...

Research Analysts Set Expectations for CorMedix Q1 Earnings

CorMedix Inc (NASDAQ:CRMD - Free Report) - HC Wainwright issued their Q1 2026 earnings per share estimates for CorMedix in a research note issued on Friday, January 23rd. HC Wainwright analyst B...

Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?

CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.82	--	--	N/A
Q3 '25	$0.63	$1.26	98.65%	BEAT
Q2 '25	$0.19	$0.29	54.96%	BEAT
Q1 '25	$0.26	$0.30	15.38%	BEAT
Q4 '24	$0.13	$0.22	67.09%	BEAT

CRMD
CorMedix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest CRMD News

CRMDCorMedix Inc